AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer

...double-blind, parallel-group, multi-centre study evaluating the efficacy of zactima 300mg plus best supportive care versus best supportive care in patients wit...double-blind, placebo-controlled, multi-centre study, evaluating once-daily zactima 300mg as a monotherapy in advanced medullary thyroid cancer. About ...

Drug Trials Show Modest Gains Against Lung Cancer

... Alimta, zactima extend survival but cure remains out of reach, stu...dvanced non-small cell lung cancer taking the drug zactima (vandetanib). Researchers found that adding the me...free survival. Unlike other lung cancer drugs, zactima packs a one-two punch, targeting two separate cell...

Zactima in Medical Technology

AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer

...of the world's most respected biopharmaceutical employers. For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com zactima is a registered trademark of the AstraZeneca group of companies. (1) Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC:...

Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

...y at the University of Texas MD Anderson Cancer Centre . "The results of Study 6 provide encouraging support, and reinforce further investigation with zactima in combination with chemotherapy in Phase III trials." Based on these data, AstraZeneca has initiated a Phase III trial, currently underway, to evalu...

Zactima in Biological Technology

AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016

Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen's Efficacy, According to a New Report from Decision Resources WALTHAM, Mass., March 20 /PRNewswire/ -- Decision Resources, one of the world's leading...

AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)

...listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com . zactima is a registered trademark of the AstraZeneca group of companies. (1) Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC:...